Similar articles

• [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].

  Pérol M. Pérol M. Rev Pneumol Clin. 2006 Feb;62 Spec no 1:1S30-4. Rev Pneumol Clin. 2006. PMID: 16719154 French. No abstract available.
• Salvage with erlotinib plus bevacizumab: not in NSCLC.

  Sculier JP, Meert AP, Berghmans T. Sculier JP, et al. Lancet. 2011 May 28;377(9780):1810-2. doi: 10.1016/S0140-6736(11)60740-X. Lancet. 2011. PMID: 21621709 No abstract available.
• Newer opportunities in systemic therapy of lung cancer.

  Rajan A, Gutierrez M, Giaccone G. Rajan A, et al. Ann Oncol. 2008 Sep;19 Suppl 7(Suppl 7):vii31-7. doi: 10.1093/annonc/mdn445. Ann Oncol. 2008. PMID: 18790973 Free PMC article. No abstract available.
• [New biological treatments for lung cancer].

  Zalcman G, Richard N, Bergot E. Zalcman G, et al. Rev Pneumol Clin. 2007 Feb;63(1):20-8. doi: 10.1016/s0761-8417(07)90085-1. Rev Pneumol Clin. 2007. PMID: 17457280 Review. French.
• Angiogenesis inhibition in the treatment of lung cancer.

  Vokes E, Herbst R, Sandler A. Vokes E, et al. Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17143257 Review.